Dermatology Times July 2026 Recap

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.

A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.

At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.

Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.

October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.

Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.